Status of Usage of Anti-vascular Endothelial Growth Factor in Age-related Macular Degeneration
10.3341/jkos.2019.60.8.758
- Author:
Songhee CHO
1
;
Sang Jin SHIN
;
Jae Kyung SUH
;
Hajin TCHOE
;
Min Joo KANG
;
Jangmi YANG
;
Donghyun JEE
Author Information
1. Economic Evaluation Team, National Evidence Based Health Care Collaborating Agency, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Age-related macular degeneration;
Intravitreal injection;
Public health Korea;
Ranibizumab
- MeSH:
Diagnosis;
Endothelial Growth Factors;
Humans;
Insurance;
Intravitreal Injections;
Macular Degeneration;
National Health Programs;
Public Health;
Ranibizumab
- From:Journal of the Korean Ophthalmological Society
2019;60(8):758-764
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To evaluate the current use of intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) in patients with age-related macular degeneration (AMD). METHODS: We analyzed the number and medical costs of patients with AMD diagnosed by the National Health Insurance Corporation (2007–2016). We also analyzed the number and medical costs of such patients who received anti-VEGF treatment, and analyzed the frequency, period of use, and average medical cost of anti-VEGF use in AMD patients. Finally, we evaluated the use of anti-VEGF injections for new AMD patients. RESULTS: The number of patients with AMD was 236,158 in 2009 and 537,528 in 2016, which represented a 2.3-fold increase over 8 years. Of these, the number of patients undergoing anti-VEGF therapy increased steadily from 9,961 in 2009 to 35,762 in 2016. The mean number of cycles of ranibizumab or aflibercept per patient was 4.87 ± 3.37, and the mean interval between treatments was 2.89 months. On average, 6.2 injections were performed in the first year of diagnosis, and the frequency of use decreased with time, with an average of 1.2 cycles after 4 years of diagnosis. Among all AMD patients in 2016, the total medical cost of those treated with anti-VEGF was 76.9 billion won, and the average medical cost per person was 2,162,145 won. CONCLUSIONS: The use of two drugs, ranibizumab and aflibercept, as reflected in public health insurance claims, steadily increased over the study period. Notably, there was a tendency to substitute aflibercept for ranibizumab.
